IOL Chemicals Announces Capacity Expansion for Triacetin and Pantoprazole; Releases Audited Financial Results
IOL Chemicals and Pharmaceuticals Limited announced that its Board of Directors, at a meeting held on May 20, 2026, approved the audited Standalone and Consolidated Financial Statements and financial results for the financial year and quarter ended March 31, 2026.The company also announced that its 39th Annual General Meeting (AGM) has been fixed for September 2, 2026, to be held via Video Conferencing/Other Audio Visual Means. The closure period for the Register of Members and Share Transfer for this AGM will be from August 27, 2026, to September 2, 2026.
Capacity Expansion and Product Portfolio Strengthening
The Board also approved strategic expansions of the company’s manufacturing capabilities.The key operational approvals include:
- Triacetin Plant Installation: Approval was granted for the installation of manufacturing facilities for the new product, Triacetin. This project involves completing manufacturing facilities at the existing plant in Barnala in a phased manner. Phase I has a proposed manufacturing capacity of 6000 MTPA. The initiative aims to expand the product portfolio and strengthen the company's presence in value-added sectors, leveraging Triacetin, an oily liquid used in the food, pharmaceutical, cosmetic, and industrial sectors. The entire capital expenditure for this project was funded through internal accruals.
- Pantoprazole Enhancement: The company also approved enhancing the installed manufacturing capacity of Pantoprazole at its Barnala plant. The capacity will increase from 240 MTPA to 276 MTPA, funded entirely through internal accruals.
Details regarding these projects confirm that the expansion of 'Triacetin' is designed to diversify the product portfolio, while the Pantoprazole enhancement is aimed at meeting growing demand through higher production volumes.
Financial Highlights
The company released comprehensive consolidated and standalone financial results for the quarter and year ended March 31, 2026. Statutory Auditors, Ashwani & Associates, issued an Unmodified Opinion on the financial statements.The key financial data for the company for the respective periods are detailed below:
Consolidated Financial Results Summary (Rs in Crore)
| Particulars | Quarter ended 31-Mar-2026 (Unaudited) | Quarter ended 31-Dec-2025 | Quarter ended 31-Mar-2025 | Year ended 31-Mar-2026 | Year ended 31-Mar-2025 |
|---|---|---|---|---|---|
| Total income | 621.29 | 585.68 | 532.31 | 2,340.44 | 2,101.62 |
| Total expenses | 550.48 | 546.92 | 487.61 | 2,144.87 | 1,963.66 |
| Profit before tax | 70.81 | 27.55 | 44.70 | 184.36 | 137.96 |
| Total tax expense | 17.65 | 6.97 | 13.28 | 46.72 | 36.89 |
| Total Comprehensive Income | 55.87 | 20.72 | 31.44 | 140.24 | 99.63 |
| Earnings per share (Basic and Diluted) | 1.81 | 0.70 | 1.07 | 4.69 | 3.44 |
Consolidated Balance Sheet Summary (Rs in Crore)
| Particulars | As at 31-Mar-2026 (Audited) | As at 31-Mar-2025 |
|---|---|---|
| Total Non-current Assets | 1,359.32 | 1,230.73 |
| Property, plant and equipment | 1,165.38 | 1,158.37 |
| Capital work-in-progress | 93.61 | 20.81 |
| Total Current Assets | 1,227.63 | 1,151.34 |
| Trade receivables | 603.13 | 513.69 |
| Cash and cash equivalents | 65.35 | 78.17 |
| TOTAL ASSETS | 2,586.95 | 2,382.07 |
| Total Equity | 1,798.55 | 1,687.66 |
| Total Non-current Liabilities | 98.22 | 84.5 |
| Total Current Liabilities | 690.18 | 609.91 |
| TOTAL EQUITY AND LIABILITIES | 2,586.95 | 2,382.07 |
The standalone and consolidated financial results, including a segment-wise breakdown, are available on the company's website. The company also noted that it has incorporated a wholly owned subsidiary, IOL Pharmaxis UK Limited, in the United Kingdom, though business operations have not yet commenced.
IOLCP Stock Price Movement
Today, IOL Chemicals and Pharmaceuticals Limited shares rallied, concluding the trading session at ₹116.03, reflecting a solid 5.37% gain. The equity saw substantial market interest, trading on a total volume of 10.83 million shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.